Evidence map›Paper›PMID 24217129›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

JoAnn Difede, Judith Cukor, Katarzyna Wyka, Megan Olden, Hunter Hoffman, Francis S Lee, Margaret Altemus

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04611399 (MIND-VR), which is not on this map. Cited by 90 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 6 pooled it
7.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04611399 nacompletednot on this mapstarted 2021, after this paper: background citation

MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support

TypeinterventionalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2021 to 2023Enrolled30ConditionsStress Related DisorderArmsVR for psychoeducation and relaxation, Control (CR)
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Randomized controlled experimental study of hydrocortisone and D-cycloserine effects on fear extinction in PTSD.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

JoAnn Difede1] Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA [2] NewYork-Presbyterian Hospital, New York, NY, USA.
Judith Cukor1] Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA [2] NewYork-Presbyterian Hospital, New York, NY, USA.
Katarzyna WykaDepartment of Psychiatry, Weill Cornell Medical College, New York, NY, USA.
Megan Olden1] Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA [2] NewYork-Presbyterian Hospital, New York, NY, USA.
Hunter HoffmanDepartment of Mechanical Engineering, Human Interface Technology Laboratory, and Human Photonics Laboratory, University of Washington, Seattle, WA, USA.
Francis S Lee1] Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA [2] NewYork-Presbyterian Hospital, New York, NY, USA.
Margaret Altemus1] Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA [2] NewYork-Presbyterian Hospital, New York, NY, USA.
Cornell University · USNew York Hospital Queens · USInterface (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viewing post-traumatic stress disorder (PTSD) as a disorder of emotional learning, this study used a cognitive enhancer synergistically with virtual reality exposure (VRE) therapy for the treatment of PTSD. The main objective was to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the efficacy of the psychotherapy. Pre-clinical studies suggest that when fear extinction occurs during DCS administration, neuroplasticity may be enhanced. VRE therapy is a particularly promising format to test the hypothesis that DCS enhances extinction learning, as sensory fear cues are standardized across patients. In a pilot randomized, double-blind, placebo-controlled trial, 100 mg of DCS or placebo was administered 90 min before each weekly VRE session, to ensure peak plasma concentrations during the sessions in 25 patients with chronic PTSD. The primary outcome measure was the Clinician Administered PTSD Scale (CAPS). Secondary outcome measures included the Beck Depression Inventory-II and the State-Trait Anger Expression Inventory-2. Assessments occurred at pre-treatment, following sessions 3, 6, 10, post-treatment, and at 6 months. The difference in CAPS between the VRE-DCS (n=13) and VRE-placebo (n=12) groups increased over time beginning at 6 weeks, with medium to large between-group effect sizes immediately post-treatment and 6 months later (d=0.68 and d=1.13, respectively). A similar pattern was observed for depression, anger expression, and sleep. PTSD remission rates were significantly greater for the VRE-DCS group (46% vs 8% at post-treatment; 69% vs 17% at 6 months). Patients in the VRE-DCS group showed earlier and greater improvement in PTSD symptoms compared with the VRE-placebo group. These results suggest a promising new treatment for PTSD.

Indexed as

Implosive TherapyAdultAgedAngerChemotherapy, AdjuvantChronic DiseaseCycloserineDepressionDouble-Blind MethodExtinction, PsychologicalFearFemaleHumansMaleMiddle AgedPilot ProjectsCycloserinePsychotropic Drugs

Identifiers

PMID24217129
PMCPMC3957110
OpenAlexW1994673996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.